Study Finds Alternative to Statins in Preventing Heart Attacks and Strokes
▻http://www.nytimes.com/2014/11/18/health/study-finds-alternative-to-statins-in-preventing-heart-attacks-and-strokes.
L’étude citée n’avait pas pour objet de prouver que le produit testé (Ezetimibe) pouvait constituer un substitut aux statines contrairement à ce qu’affirme le titre de l’article (qui prend bien soin de donner le nom commercial du produit)
L’élément interessant, lu en fin d’article, est que l’Ezetimibe avait été jusque là promu et commercialisé (30 milliards USD de ventes) sans preuve réelle de son efficacité :
“Now we have the result,” Dr. Nissen said. “They were successful, and that’s great. But at this point, it really doesn’t matter. They made their $30 billion.” The drug will be available as a generic in 2016, Merck says.
The fact that the drug was promoted and sold for so many years without evidence that it helped was inexcusable, Dr. Krumholz said.
“The fact that the trial exists says there was uncertainty,” Dr. Krumholz said. “The company and the investigators and the scientific community were uncertain about it. This is a cautionary tale,” he added. “The results could easily have gone the other way.”